Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SQOR | Q9Y6N5 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011446 | 0.89 | ALDH1A1 (0.44) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7022182 | 0.88 | MAPK8 (0.47) | ALDH1A1HSD17B10MAPK8MAPK9GAA | |
| SCHEMBL7021596 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7021434 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7022639 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7018816 | 0.88 | ALDH1A1 (0.48) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7013301 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7020733 | 0.87 | ALDH1A1 (0.45) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL7020448 | 0.87 | ALDH1A1 (0.43) | ALDH1A1HSD17B10MAPK1MAPK8MAPK9 | |
| SCHEMBL28750844 | 0.86 | ADORA2A (0.47) | ALDH1A1HSD17B10MAPK1GAAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | claimed |
| CN-1441783-A | Drug containing dicyanopyridine derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-10 | — | — | CN | claimed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | claimed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| CN-1441783-A | Drug containing dicyanopyridine derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | ALDH1A1 3292/4885HSD17B10 3642/4885MAPK1 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.